Advertisement

Orthopädie & Rheuma

, Volume 22, Issue 2, pp 20–28 | Cite as

Symptome, Diagnostik, Verlauf und Therapie

Axiale Spondyloarthritis: Am Anfang steht der entzündliche Rückenschmerz

  • Dieter SchöffelEmail author
Zertifizierte Fortbildung

Zusammenfassung

Die axiale Spondyloarthritis ist eine Erkrankung, deren Vollbild über Jahrzehnte als Spondylitis ankylosans (Morbus Bechterew) bekannt war. Charakteristisch sind entzündliche Schmerzen der Wirbelsäule, Bewegungseinschränkungen sowie strukturelle Veränderungen der Iliosakralgelenke und der Wirbelsäule. Es besteht eine genetische Disposition und eine Assoziation mit diversen anderen Erkrankungen wie der Psoriasis oder chronisch entzündlichen Darmerkrankungen. Insbesondere dank der erheblich verbesserten Therapiemöglichkeiten ist der früher schicksalhafte Verlauf heutzutage gut beeinflussbar.

Literatur

  1. 1.
    Braun, J., et al., Prevalence of spondylarthropathie s in HLA-B27 positive and negative blood donors. Arthritis Rheum, 1998 41 (1): p. 58–67.CrossRefGoogle Scholar
  2. 2.
    Zink, A., et al., Disability and handicap in rheumatoid arthritis and ankylosing spondylitis—results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol, 2000. 27(3): p. 613–22PubMedGoogle Scholar
  3. 3.
    Vander Cruyssen, B., et al., The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann Rheum Dis, 2007. 66 (8): p. 1072–7.CrossRefGoogle Scholar
  4. 4.
    Peters, M.J., et al., Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum, 2004; 34, (3): p. 585–92CrossRefGoogle Scholar
  5. 5.
    Kiltz U. Baraliakos X, Borg AA. Spondyloarthropathies: Pathogenesis and Clinical Features. EULAR Textbook on Rheumatology 2016Google Scholar
  6. 6.
    Rudwaleit M, Haibel H, Baraliakos X et al., The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum, 2009. 60(3): p. 717–27CrossRefGoogle Scholar
  7. 7.
    van den Berg R, Lenczner G, FEydy A et al. Agreement between clinical practice and trained central reading in reading of plain pelvic radiographs. Results oft he DESIR cohort. Arthritis Rheumatol 2014, 66: 24032411Google Scholar
  8. 8.
    van Tubergen A, Heuft-Dorenbosch L, Schulpen G et al. Radiographic assessment ofsacroiliitis by radiologists and rheumatologists. Does training improve quality? Ann Rheum Dis 2003, 62, 19–25Google Scholar
  9. 9.
    Baraliakos X1, van der Heijde D, Braun J, Landewé RB. OMERACT magnetic resonance imaging initiative on structural and inflammatory lesions in ankylosing spondylitis—report of a special interest group at OMERACT 10 on sacroiliac joint and spine lesions. J Rheumatol. 2011 Sep;38(9):2051–4CrossRefGoogle Scholar
  10. 10.
    Song, I.H., et al., The diagnostic value of scintigraphy in assessing sacroiliitis in ankylosing spondylitis: a systematic literature research. Ann Rheum Dis, 2008. 67(11): p. 1535–40CrossRefGoogle Scholar
  11. 11.
    AWMF-Leitlinie „Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen“, Register-Nr. 060/003, S3-Leitlinie, Version November 2013.Google Scholar
  12. 12.
    Deodhar A, Strand V, Kay J und Braun J. The term „non-radiographic axial spondyloarthritis“ is much more important to classify than to diagnose patients with axial spondyloarthritis. Ann Rheum Dis 2016, 75: 791–794CrossRefGoogle Scholar
  13. 13.
    Rudwaleit M, Landewe R, van der Hejde D et al. The development of Assessment of SpondyloArthritis International Society (ASAS) classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 2009; 68, 770–776CrossRefGoogle Scholar
  14. 14.
    Rudwaleit M, van der Hejde D, Landewe R et al. The development of Assessment of SpondyloArthritis International Society (ASAS) classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009; 68, 777–783CrossRefGoogle Scholar
  15. 15.
    Baraliakos, X, Listing J, Rudwaleit M et al. Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis, 2007. 66 (7): p. 910–915CrossRefGoogle Scholar
  16. 16.
    Poddubnyy, D., et al., Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum, 2012. 64(5): p. 1388–98.CrossRefGoogle Scholar
  17. 17.
    Sampaio-Barros PD, Bortoluzzo AB, Conde RA et al. Undifferentiated Sondyloarthritis: a longterm follow-up. J Rheumatol 2010; 37, 1195–1199)CrossRefGoogle Scholar
  18. 18.
    Garrett S, Jenkinson T, Kennedy LG et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286–91.PubMedGoogle Scholar
  19. 19.
    Lukas C, Landewé R, Sieper J, Dougados M, Davis J, Braun J, van der Linden S, van der Heijde D. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:18–24CrossRefGoogle Scholar
  20. 20.
    Lim, H.J., Y.I. Moon, and M.S. Lee, Effects of home-based daily exercise therapy on joint mobility, daily activity, pain, and depression in patients with ankylosing spondylitis. Rheumatol Int, 2005. 25(3): p. 225–9CrossRefGoogle Scholar
  21. 21.
    Passalent, L.A., et al., vExercise in ankylosing spondylitis: discrepancies between recommendations and reality. J Rheumatol, 2010. 37(4): p. 835–41.CrossRefGoogle Scholar
  22. 22.
    Wanders, A., et al., Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum, 2005. 52(6): p. 1756–65.CrossRefGoogle Scholar
  23. 23.
    Kroon, F, Landewé, R, Dougados, M. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis 2012; 71: 1623–162CrossRefGoogle Scholar
  24. 24.
    Sieper J, Listing J, Poddubnyy D. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Ann Rheum Dis 2016;75:1438–43CrossRefGoogle Scholar
  25. 25.
    Chen J, Lin S, Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev, 2005(2): p. CD004800Google Scholar
  26. 26.
    van der Heijde D, Ramiro S, Landewé R et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017 Jun; 76(6):978–991CrossRefGoogle Scholar
  27. 27.
    Maugars, Y., et al., Assessment of the efficacy of sacroiliac corticosteroid injections in spondylarthropathies: a double-blind study. Br J Rheumatol, 1996. 35(8): p. 767–70CrossRefGoogle Scholar
  28. 28.
    Zochling J, van der Heijde D, Dougados M, Braun J. Current evidence for the manage ment of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis, 2006. 65(4): p. 423–32CrossRefGoogle Scholar
  29. 29.
    Visvanathan, S., et al., Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis, 2009. 68 (2): p. 175–82CrossRefGoogle Scholar
  30. 30.
    Dougados, M., et al., Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). Ann Rheum Dis, 2011. 70(5): p. 799–804CrossRefGoogle Scholar
  31. 31.
    van der Heijde D, Baraliakos X, Hermann KA et al. Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPIDaxSpA phase III randomised trial. Ann Rheum Dis. 2018 May;77(5): 699–705CrossRefGoogle Scholar
  32. 32.
    Mease P. van der Heijde D, Ritchlin C et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017 Jan; 76(1): 79–87CrossRefGoogle Scholar
  33. 33.
    Sepriano A, Regel A, van der Heijde D, Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. RMD Open. 2017 Jan 27;3(1)Google Scholar
  34. 34.
    van der Heijde D, Cheng-Chung Wei J, Dougados M et al. Ixekizumab, an interleukin17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying antirheumatic drugs. Lancet 2018; 392, 2441–2451.CrossRefGoogle Scholar
  35. 35.
    Song IH, Heldmann F, Rudwaleit M et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis 2011;70:1108–10CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Osteologisches SchwerpunktzentrumMannheimDeutschland

Personalised recommendations